DK2078022T3 - Spirobenzazepiner anvendt som vasopressinantagonister - Google Patents

Spirobenzazepiner anvendt som vasopressinantagonister

Info

Publication number
DK2078022T3
DK2078022T3 DK07842799.4T DK07842799T DK2078022T3 DK 2078022 T3 DK2078022 T3 DK 2078022T3 DK 07842799 T DK07842799 T DK 07842799T DK 2078022 T3 DK2078022 T3 DK 2078022T3
Authority
DK
Denmark
Prior art keywords
renal
hyponatremia
hypertension
insufficiency
formula
Prior art date
Application number
DK07842799.4T
Other languages
Danish (da)
English (en)
Inventor
Min A Xiang
Mona Patel
Philip Rybczynski
Joseph Gunnet
Keith T Demarest
Richard Look
Michael J Costanzo
Stephen C Yabut
Bruce Maryanoff
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK2078022T3 publication Critical patent/DK2078022T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK07842799.4T 2006-09-22 2007-09-19 Spirobenzazepiner anvendt som vasopressinantagonister DK2078022T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82665406P 2006-09-22 2006-09-22
PCT/US2007/078917 WO2008036755A1 (en) 2006-09-22 2007-09-19 Spiro benzazepines used as vasopressin antagonists

Publications (1)

Publication Number Publication Date
DK2078022T3 true DK2078022T3 (da) 2012-02-13

Family

ID=39030853

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07842799.4T DK2078022T3 (da) 2006-09-22 2007-09-19 Spirobenzazepiner anvendt som vasopressinantagonister

Country Status (14)

Country Link
US (1) US7825110B2 (enExample)
EP (1) EP2078022B1 (enExample)
JP (1) JP2010504351A (enExample)
CN (1) CN101541806A (enExample)
AT (1) ATE532786T1 (enExample)
AU (1) AU2007299818B2 (enExample)
CA (1) CA2665849A1 (enExample)
CY (1) CY1112270T1 (enExample)
DK (1) DK2078022T3 (enExample)
ES (1) ES2374582T3 (enExample)
PL (1) PL2078022T3 (enExample)
PT (1) PT2078022E (enExample)
SI (1) SI2078022T1 (enExample)
WO (1) WO2008036755A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6050238B2 (ja) * 2011-10-19 2016-12-21 興和株式会社 新規なスピロインドリン化合物、及びそれを含有する医薬
EA201790185A1 (ru) 2014-07-15 2017-07-31 Грюненталь Гмбх Замещенные азаспиро(4.5)декановые производные
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
EP3321271B1 (en) 2015-07-07 2024-05-29 Japan Tobacco Inc. Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof
MX2019007542A (es) 2016-12-21 2019-11-18 Japan Tobacco Inc Proceso para la preparación de derivados de 7h-pirrolo [2, 3-d] pirimidina y sus intermedios sintéticos.
MY208313A (en) 2017-09-15 2025-04-30 Azevan Pharmaceuticals Inc Compositions and methods for treating brain injury
WO2019141575A1 (de) 2018-01-16 2019-07-25 Bayer Aktiengesellschaft Unterstützung bei der behandlung von herzinsuffizienz
EP4192957A4 (en) * 2020-08-07 2024-09-04 Casma Therapeutics, Inc. Trpml modulators
EP4253367A4 (en) * 2020-11-26 2024-10-23 Shanghai Jemincare Pharmaceuticals Co., Ltd. NOVEL BENZAZEPINESPIRO DERIVATIVE
CN112939864B (zh) * 2021-01-29 2022-05-06 中国医科大学 螺[苯并[c]氮杂-1,1’-环己基]-3-酮类化合物
EP4491699A1 (de) 2023-07-13 2025-01-15 Klueber Lubrication München GmbH & Co. KG Phthalimidverbindungen als basisöl für schmierstoffzusammensetzungen
WO2026002248A1 (zh) * 2024-06-28 2026-01-02 上海济煜医药科技股份有限公司 作为v2受体拮抗剂的苯并氮杂卓并环衍生物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
JP2905909B2 (ja) * 1991-04-19 1999-06-14 大塚製薬株式会社 バソプレシン拮抗剤
US5985869A (en) 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
WO1991005549A1 (en) 1989-10-20 1991-05-02 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
FR2708605A1 (fr) 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5849780A (en) 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2686878B1 (fr) * 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5686624A (en) 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
JPH08502474A (ja) 1992-10-07 1996-03-19 メルク エンド カンパニー インコーポレーテッド トコリティックオキシトシンレセプターアンタゴニスト
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
HUP0301590A3 (en) * 2000-07-05 2005-01-28 Ortho Mcneil Pharm Inc Nonpeptide substituted spirobenzoazepines as vasopressin antagonists, pharmaceutical compositions containing them and their preparation
CA2432825A1 (en) * 2000-12-15 2002-06-20 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
US7011898B2 (en) * 2003-03-21 2006-03-14 Air Products And Chemicals, Inc. Method of joining ITM materials using a partially or fully-transient liquid phase
EA200501829A1 (ru) * 2003-06-17 2006-06-30 Янссен Фармацевтика Н. В. Способ получения непептидных замещённых спиробензоазепиновых производных
ES2332724T3 (es) * 2003-06-17 2010-02-11 Janssen Pharmaceutica Nv Espirobenzoazepinas sustituidas.
JP2009523806A (ja) * 2006-01-20 2009-06-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ （４ｒ）−１−［４−（２−クロロ−５−フルオロベンゾイル）アミノ−３−メトキシベンゾイル］−１，２，３，５−テトラヒドロ−スピロ［４ｈ−１−ベンズアゼピン−４，１’−［２］シクロペンテン］−３’−カルボン酸の新規固体形態物

Also Published As

Publication number Publication date
US7825110B2 (en) 2010-11-02
CA2665849A1 (en) 2008-03-27
SI2078022T1 (sl) 2012-01-31
EP2078022B1 (en) 2011-11-09
PT2078022E (pt) 2012-01-11
EP2078022A1 (en) 2009-07-15
AU2007299818B2 (en) 2012-08-02
JP2010504351A (ja) 2010-02-12
AU2007299818A1 (en) 2008-03-27
CY1112270T1 (el) 2015-12-09
US20080076753A1 (en) 2008-03-27
WO2008036755A1 (en) 2008-03-27
ES2374582T3 (es) 2012-02-20
PL2078022T3 (pl) 2012-04-30
ATE532786T1 (de) 2011-11-15
CN101541806A (zh) 2009-09-23

Similar Documents

Publication Publication Date Title
ATE532786T1 (de) Spirobenzazepine als vasopressinantagonisten
EA201171361A1 (ru) Ингибиторы внешнего медуллярного калиевого канала почек
MA33358B1 (fr) Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase
EA201070339A1 (ru) Активаторы растворимой гуанилатциклазы
UA117929C2 (uk) Сполуки піримідиндіону, спрямовані проти станів серцево-судинної системи
CR20140316A (es) Derivados de indol como antagonistas receptores de s1p1 (divisional 10922)
EA200900811A1 (ru) Имидазолы в качестве ингибиторов альдостеронсинтазы
CO6220853A2 (es) Derivados de pentafluorotiobenzamido acetonitrilo como agentes antiparasitarios
MY128065A (en) Tricyclic benzodiazepines as vasopressin receptor antagonists
MA35032B1 (fr) Derives de glycoside et leurs utilisations dans le traitement du diabete
CR20110209A (es) Composición farmacéutica sólida
CY1109585T1 (el) Υποκατεστημενες σπειροβενζαζεπινες
DK1307430T3 (da) Ikke-peptidsubstituerede spirobenzoazepiner som vasopressin-antagonister
DE602008005711D1 (de) Amidsubstituierte indazole als poly-(adp-ribose)-polymerase (parp)-hemmer
ATE557019T1 (de) Pyrrolidin-3-ylmethyl-amin als orexin- antagonisten
MX2013004739A (es) Derivados heterociclicos de diazenodiolato.
EA200801549A1 (ru) Новые производные фенантридина в качестве антагонистов брадикинина
DK1214323T3 (da) Indoloazepiner som vasopressinreceptorantagonister
MXPA02004513A (es) Benzotiazefinas sustituidas no peptidicas como antagonistas de vasopresina.
WO2006049984A3 (en) Novel [1,4]benzodiazepines as vasopressin v2 receptor antagonists
NZ622549A (en) Novel crystalline form of zofenopril calcium